Momenta Pharmaceuticals (NASDAQ: MNTA) is one of 191 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Momenta Pharmaceuticals to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.
Insider & Institutional Ownership
93.7% of Momenta Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 4.4% of Momenta Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of current ratings and recommmendations for Momenta Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Momenta Pharmaceuticals Competitors||512||2432||6621||122||2.66|
Momenta Pharmaceuticals currently has a consensus target price of $14.44, suggesting a potential upside of 5.43%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 16.65%. Given Momenta Pharmaceuticals’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Momenta Pharmaceuticals has less favorable growth aspects than its rivals.
This table compares Momenta Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Momenta Pharmaceuticals Competitors||-3,394.93%||-529.12%||-40.09%|
Risk and Volatility
Momenta Pharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals’ rivals have a beta of 1.53, indicating that their average share price is 53% more volatile than the S&P 500.
Earnings & Valuation
This table compares Momenta Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Momenta Pharmaceuticals||$109.62 million||-$21.00 million||-17.13|
|Momenta Pharmaceuticals Competitors||$213.37 million||-$39.02 million||-65.33|
Momenta Pharmaceuticals’ rivals have higher revenue, but lower earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company’s Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company’s programs include M254, M281 (Anti-FcRn candidate) and M230.
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.